Docoh
Loading...

CORV Correvio Pharma

Correvio Pharma Corp. is a specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Correvio's pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.

Company profile

Ticker
CORV
Exchange
CEO
Mark H. N. Corrigan
Employees
Fiscal year end
Former names
Cardiome Pharma Corp, Cardiome Pharma Corp, Nortran Pharmaceuticals Inc
SEC CIK

CORV stock data

(
)

Calendar

29 Apr 20
13 Apr 21
31 Dec 21

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

6.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 26 30 -13.3%
Opened positions 4 8 -50.0%
Closed positions 8 17 -52.9%
Increased positions 7 5 +40.0%
Reduced positions 5 9 -44.4%
13F shares
Current Prev Q Change
Total value 1.65M 1.87M -11.7%
Total shares 4.26M 4.57M -6.9%
Total puts 0 16.3K EXIT
Total calls 15.6K 30.3K -48.5%
Total put/call ratio 0.5
Largest owners
Shares Value Change
Beryl Capital Management 2.38M $924K NEW
JBF Capital 363.53K $141K NEW
Renaissance Technologies 278.4K $108K +15.7%
Summer Road 250K $97K 0.0%
Two Sigma Advisers 230.9K $90K +17.7%
Citadel Advisors 168.27K $65K +64.8%
UBS UBS Group AG - Registered Shares 101.39K $39K +322.4%
Susquehanna International 91.41K $35K -13.6%
JPM JPMorgan Chase & Co. 69.95K $27K -48.7%
LPLA LPL Financial 66.76K $26K 0.0%
Largest transactions
Shares Bought/sold Change
Tamarack Advisers 0 -2.5M EXIT
Beryl Capital Management 2.38M +2.38M NEW
JBF Capital 363.53K +363.53K NEW
VIRT Virtu Financial 0 -287.97K EXIT
ARS Investment Partners 0 -147.82K EXIT
Oxford Asset Management 0 -116.65K EXIT
Royce & Associates 0 -101.1K EXIT
MS Morgan Stanley 3.9K -95.95K -96.1%
UBS UBS Group AG - Registered Shares 101.39K +77.39K +322.4%
JPM JPMorgan Chase & Co. 69.95K -66.42K -48.7%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Aboriginal, acknowledged, Adherium, ADVANZ, aforce, AGGRASTATare, AGGRASTATlabel, AMAG, ancestry, andare, Andersen, AptivusTM, Arena, ArQule, artificially, background, battery, behavior, Belgian, Berry, Bio, Biosense, biosimilar, Blueprint, book, bore, bound, boutique, Brexit, BRFBR, Byron, Calgary, Camptosar, Canary, canvassing, car, ceftazidime, ceiling, Chiesi, Chimerix, Cian, CidofovirTM, Coast, Codification, colder, color, complaint, compliant, complimentary, Congressional, conviction, copyright, Corcept, Cornell, CORV, Corvert, counter, CRDAC, CRL, Cubicin, Defense, deleting, delist, delisted, delisting, Depositary, disaggregated, disagreement, discrimination, diverted, DPA, earliest, economy, embezzlement, embracing, EMEA, EMV, entitledmultiplied, enumerated, Ethicon, EU, evidentiary, exploit, failureor, fallen, Falsified, Farmaceutici, fear, feedback, fifteen, FoscarnetTM, French, furtheralign, Gas, GDPR, genericization, Gibraltar, grantedmultiplied, Gulf, GXP, hear, hearing, HHS, Holderprovided, Holy, immovable, impulse, inadvertent, Inernal, instalment, Iran, Iranian, irrespective, JD, landscape, Latin, lawsuit, learn, Lebanese, lecturer, linezolid, Lisbon, Liverpool, Lord, Luxembourg, Lybrand, mainland, majeure, marital, Master, maximize, membership, Memorandum, Mercury, Millipore, mineral, Ministerial, Mirapex, mobility, multijurisdictional, MycobutinTM, Nabriva, negligence, nonoperating, Northeastern, Northwestern, Novelion, Novo, occupied, OFAC, offside, Oilfield, Olympic, Orchestra, outbreak, outreach, pandemic, parent, Parma, PeBen, Pharmacopeia, Piper, piperacillin, productsand, proper, prorated, Prostrakan, psychiatry, purportedly, Queen, race, reassuring, referendum, regime, religion, Renal, Rescriptor, RescriptorTM, Riley, rollout, Sandler, sat, secondary, securityholder, sensor, sex, sexual, sixteen, slight, slowdown, smart, Southern, stakeholder, Sucampo, Suffolk, SummatiX, summer, Sunovion, Symphony, Tabular, tazobactam, teicoplanin, tender, Teson, theft, timber, TM, today, tracking, traditionally, transmission, transparency, travel, Tremeau, tribunal, Trump, turnover, UAE, unapproved, uncontrolled, unreliable, usufruct, Vanda, vehicle, verification, virtual, virtually, visible, visit, Wainwright, waive, waived, wear, weather, Webster, winter, Xalatan, Xopenex, Zinforo, Zogenix
Removed: Alliance, arm, Biotech, blockade, body, caliber, catheter, chronic, Commerce, converting, delivered, Directorate, disposed, effected, formed, half, heritage, initiation, introduced, inventor, ion, largely, length, liable, magnitude, Nortran, post, pursued, recipient, restructuring, returned, selective, shipment, theCompany, TPD, UK, ventricular, venture, WTO, young

Proxies

No filings